Patent-to-Launch Time for Orphan Drugs is 2.3 Years Longer vs. Other Drugs, According to the Tufts Center for the Study of Drug Development
09 mai 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Orphan drug development, which faces special challenges in recruiting sufficient numbers of patients for clinical trials, on average takes 15.1 years to go...
First Comprehensive Clinical Site Initiation Benchmark, Developed by Tufts Center for the Study of Drug Development, Finds Study Startup Is Lengthy and Inefficient
07 mars 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- The clinical site initiation process—time needed to identify and select sites and begin studies—takes an average of nearly eight months, longer than it did...
eClinical Data Volume and Diversity Pose Increasing Challenges and Delays, According to the Tufts Center for the Study of Drug Development
09 janv. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- The growing volume of data collected in clinical trials is contributing to longer development times and posing technical and integration challenges to...
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
09 sept. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
07 août 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
10 juil. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
08 mai 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
06 mars 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
23 janv. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
16 janv. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...